Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-315.2%
operating margin TTM
-439.09%
revenue TTM
8.50 Thousand
revenue per share TTM
0.03$
valuation ratios | |
|---|---|
| pe ratio | -0.04 |
| peg ratio | 0.00 |
| price to book ratio | -0.29 |
| price to sales ratio | 0.12 |
| enterprise value multiple | 0.44 |
| price fair value | -0.29 |
profitability ratios | |
|---|---|
| gross profit margin | 100.0% |
| operating profit margin | -439.09% |
| pretax profit margin | -338.77% |
| net profit margin | -315.2% |
| return on assets | -84.66% |
| return on equity | -1855.14% |
| return on capital employed | -181.4% |
liquidity ratio | |
|---|---|
| current ratio | 2.01 |
| quick ratio | 2.01 |
| cash ratio | 1.16 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 202.24 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 202.24 |
| receivables turnover | 1.80 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.81 |
| debt equity ratio | -6.11 |
| long term debt to capitalization | 1.26 |
| total debt to capitalization | 1.20 |
| interest coverage | -17.20 |
| cash flow to debt ratio | -0.20 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.27 |
| cash per share | 0.69 |
| operating cash flow per share | -0.27 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.20 |
| short term coverage ratios | -12.62 |
| capital expenditure coverage ratio | -2,007.00 |
Frequently Asked Questions
When was the last time Evaxion Biotech A/S (NASDAQ:EVAX) reported earnings?
Evaxion Biotech A/S (EVAX) published its most recent earnings results on 30-09-2024.
What is Evaxion Biotech A/S's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Evaxion Biotech A/S (NASDAQ:EVAX)'s trailing twelve months ROE is -1855.14%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Evaxion Biotech A/S (EVAX) currently has a ROA of -84.66%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did EVAX's net profit margin stand at?
EVAX reported a profit margin of -315.2% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is EVAX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.01 in the most recent quarter. The quick ratio stood at 2.01, with a Debt/Eq ratio of -6.11.